Industry News
Pharmaceutical Industry News
Novartis’ Leqvio to reap $2.5B by 2027 thanks to convenience edge over Amgen, Sanofi rivals: analyst
Novartis' Leqvio to reap $2.5B by 2027 thanks to convenience edge over Amgen, Sanofi rivals: analyst kdunleavy Tue, 02/22/2022 - 09:47
J&J to shutter Pennsylvania OTC manufacturing plant by 2023, report
J&J to shutter Pennsylvania OTC manufacturing plant by 2023, report jkeenan Tue, 02/22/2022 - 09:36
GlaxoSmithKline unveils Haleon, the new brand name for its outgoing consumer health unit
GlaxoSmithKline unveils Haleon, the new brand name for its outgoing consumer health unit aliu Tue, 02/22/2022 - 09:25
AstraZeneca CEO snared more than $18M last year as his company worked through highs and lows of vaccine launch
AstraZeneca CEO snared more than $18M last year as his company worked through highs and lows of vaccine launch fkansteiner Tue, 02/22/2022 - 09:07
Valneva reaps $27M development grant to boost Scottish production site
Valneva reaps $27M development grant to boost Scottish production site jkeenan Tue, 02/22/2022 - 08:38
Targeting a $300M market, Almirall starts selling ‘less greasy’ psoriasis cream in the EU
Targeting a $300M market, Almirall starts selling 'less greasy' psoriasis cream in the EU ntaylor Tue, 02/22/2022 - 06:31
AstraZeneca, Daiichi target broad breast cancer use with Enhertu’s landmark win in HER2-low disease
AstraZeneca, Daiichi target broad breast cancer use with Enhertu's landmark win in HER2-low disease aliu Tue, 02/22/2022 - 06:27
Modra, taking a leaf out of the Paxlovid playbook, validates oral delivery of chemotherapy in the clinic
Modra, taking a leaf out of the Paxlovid playbook, validates oral delivery of chemotherapy in the clinic ntaylor Tue, 02/22/2022 - 06:21
Pfizer gets EU approval for long-acting human growth hormone, softening blow of FDA rejection
Pfizer gets EU approval for long-acting human growth hormone, softening blow of FDA rejection ntaylor Tue, 02/22/2022 - 06:17
PolyActiva’s glaucoma implant cuts pressure in clinical test, opening the door to further development
PolyActiva's glaucoma implant cuts pressure in clinical test, opening the door to further development ntaylor Tue, 02/22/2022 - 06:09
U.S. House Candidate Apologizes for Behavior at Sleepover
Parents said Abby Broyles of Oklahoma drank and swore at children at a friend’s home. She said she had mixed wine with medication and had no memory of the night.
Oncologists on board for Novartis’ prostate cancer radiotherapy, but logistics could hit uptake: survey
Oncologists on board for Novartis' prostate cancer radiotherapy, but logistics could hit uptake: survey nmissakian Mon, 02/21/2022 - 11:05
¿Por qué China no ha aprobado o desarrollado una vacuna de ARNm?
El país había dicho que tenía dos vacunas con esta tecnología a su alcance y listas para ser aprobadas: una nacional y otra producida por una empresa extranjera. Hoy, ninguna de las dos está disponible.
Bristol Myers Squibb, GRYT Health double down on diversity in cancer
Bristol Myers Squibb, GRYT Health double down on diversity in cancer sharon.coey Fri, 02/18/2022 - 11:36
Sandoz launches generic Revlimid in 19 countries in Europe, opening a flood of competition for BMS’ megablockbuster
Sandoz launches generic Revlimid in 19 countries in Europe, opening a flood of competition for BMS' megablockbuster kdunleavy Fri, 02/18/2022 - 11:17
Why China Doesn’t Have an mRNA Vaccine for Covid
Beijing once said it had two mRNA shots within reach and ready for approval — one homemade and one produced by a foreign company. Today, neither is available.
Roche settles lawsuit claiming AstraZeneca’s Ultomiris infringes delivery patent
Roche settles lawsuit claiming AstraZeneca’s Ultomiris infringes delivery patent aliu Fri, 02/18/2022 - 09:51
Sanofi, Regeneron ditch Dupixent trial vs. Novartis and Roche’s Xolair for hives condition
Sanofi, Regeneron ditch Dupixent trial vs. Novartis and Roche's Xolair for hives condition kdunleavy Fri, 02/18/2022 - 09:50
Sanofi, Regeneron ditch Dupixent trial in patients who failed Novartis and Roche’s Xolair for hives condition
Sanofi, Regeneron ditch Dupixent trial in patients who failed Novartis and Roche's Xolair for hives condition kdunleavy Fri, 02/18/2022 - 09:50
Recipharm, working on Moderna’s COVID vaccine, boosts biologics presence with Arranta Bio, Vibalogics buyouts
Recipharm, working on Moderna's COVID vaccine, boosts biologics presence with Arranta Bio, Vibalogics buyouts fkansteiner Fri, 02/18/2022 - 09:47